Lung Cancer Alliance Hailed USFDA on Approval of Avastin (bevacizumab) for NSCLC
October 15, 2006 by Gloria Gamat
Filed under Diseases & Conditions
The Lung Cancer Alliance (LCA) has applauded the USFDA on its recent approval of Avastin (bevacizumab) for the most common type of lung cancer.
Laurie Fenton, President of Lung Cancer Alliance in Washington, D.C. stated:
“Lung cancer is responsible for over one-third of all U.S. cancer deaths, killing more people than breast, prostate, colon, liver and kidney cancers combined each year.
Sadly, we have few arrows in our treatment quiver to address this lethal killer. That is why the ability to use Avastin as a treatment method, along with chemotherapy, is a significant development for the lung cancer community.”
Manufactured by Genentech, Inc. (NYSE: DNA), Avastin is specifically approved for initial treatment of non-squamous, non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy for patients not eligible for surgery, or have locally advanced, recurrent or metastatic NSCLC.
The approval was based on studies where Avastin demonstrated extended survival time to 12.3 months, longer than with chemotherapy alone.
Read more at PR Newswire.
